nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—ABCC3—Fluorouracil—colon cancer	0.316	0.325	CbGbCtD
Metyrapone—ABCC3—Vincristine—colon cancer	0.288	0.296	CbGbCtD
Metyrapone—ABCC3—Methotrexate—colon cancer	0.174	0.179	CbGbCtD
Metyrapone—CYP2A6—Fluorouracil—colon cancer	0.14	0.144	CbGbCtD
Metyrapone—CYP3A4—Irinotecan—colon cancer	0.0292	0.03	CbGbCtD
Metyrapone—CYP3A4—Vincristine—colon cancer	0.0255	0.0263	CbGbCtD
Metyrapone—Bone marrow depression—Vincristine—colon cancer	0.00133	0.0659	CcSEcCtD
Metyrapone—Hirsutism—Capecitabine—colon cancer	0.00101	0.0499	CcSEcCtD
Metyrapone—Bone marrow depression—Capecitabine—colon cancer	0.000868	0.043	CcSEcCtD
Metyrapone—CYP11B2—Metapathway biotransformation—CHST4—colon cancer	0.000736	0.0998	CbGpPWpGaD
Metyrapone—ABCC3—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000654	0.0887	CbGpPWpGaD
Metyrapone—Bone marrow depression—Methotrexate—colon cancer	0.000646	0.032	CcSEcCtD
Metyrapone—CYP11B1—Metapathway biotransformation—CHST4—colon cancer	0.000634	0.086	CbGpPWpGaD
Metyrapone—Pancytopenia—Vincristine—colon cancer	0.000536	0.0265	CcSEcCtD
Metyrapone—Pancytopenia—Fluorouracil—colon cancer	0.0005	0.0247	CcSEcCtD
Metyrapone—Angiopathy—Vincristine—colon cancer	0.00041	0.0203	CcSEcCtD
Metyrapone—Alopecia—Vincristine—colon cancer	0.000399	0.0197	CcSEcCtD
Metyrapone—Angiopathy—Irinotecan—colon cancer	0.000399	0.0197	CcSEcCtD
Metyrapone—Alopecia—Irinotecan—colon cancer	0.000389	0.0192	CcSEcCtD
Metyrapone—Alopecia—Fluorouracil—colon cancer	0.000372	0.0184	CcSEcCtD
Metyrapone—ABCC3—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000358	0.0485	CbGpPWpGaD
Metyrapone—Abdominal discomfort—Capecitabine—colon cancer	0.000353	0.0174	CcSEcCtD
Metyrapone—Pancytopenia—Capecitabine—colon cancer	0.000349	0.0173	CcSEcCtD
Metyrapone—Hypertension—Vincristine—colon cancer	0.000339	0.0168	CcSEcCtD
Metyrapone—CYP11B2—Metapathway biotransformation—CHST5—colon cancer	0.000338	0.0458	CbGpPWpGaD
Metyrapone—Hypertension—Irinotecan—colon cancer	0.000331	0.0164	CcSEcCtD
Metyrapone—Nervous system disorder—Vincristine—colon cancer	0.000315	0.0156	CcSEcCtD
Metyrapone—Nervous system disorder—Irinotecan—colon cancer	0.000306	0.0152	CcSEcCtD
Metyrapone—Hypotension—Vincristine—colon cancer	0.0003	0.0148	CcSEcCtD
Metyrapone—Nervous system disorder—Fluorouracil—colon cancer	0.000293	0.0145	CcSEcCtD
Metyrapone—Hypotension—Irinotecan—colon cancer	0.000292	0.0144	CcSEcCtD
Metyrapone—CYP11B1—Metapathway biotransformation—CHST5—colon cancer	0.000291	0.0395	CbGpPWpGaD
Metyrapone—Hypotension—Fluorouracil—colon cancer	0.00028	0.0138	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Vincristine—colon cancer	0.000277	0.0137	CcSEcCtD
Metyrapone—Pain—Vincristine—colon cancer	0.000274	0.0136	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Irinotecan—colon cancer	0.00027	0.0133	CcSEcCtD
Metyrapone—Pain—Irinotecan—colon cancer	0.000267	0.0132	CcSEcCtD
Metyrapone—Angiopathy—Capecitabine—colon cancer	0.000267	0.0132	CcSEcCtD
Metyrapone—Abdominal discomfort—Methotrexate—colon cancer	0.000262	0.013	CcSEcCtD
Metyrapone—Gastrointestinal pain—Vincristine—colon cancer	0.000262	0.013	CcSEcCtD
Metyrapone—Alopecia—Capecitabine—colon cancer	0.00026	0.0129	CcSEcCtD
Metyrapone—Pancytopenia—Methotrexate—colon cancer	0.00026	0.0129	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000258	0.0128	CcSEcCtD
Metyrapone—Pain—Fluorouracil—colon cancer	0.000256	0.0127	CcSEcCtD
Metyrapone—Gastrointestinal pain—Irinotecan—colon cancer	0.000255	0.0126	CcSEcCtD
Metyrapone—Abdominal pain—Vincristine—colon cancer	0.000254	0.0125	CcSEcCtD
Metyrapone—Abdominal pain—Irinotecan—colon cancer	0.000247	0.0122	CcSEcCtD
Metyrapone—CYP11B2—ACE Inhibitor Pathway—TGFB1—colon cancer	0.000228	0.031	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—CHST4—colon cancer	0.000226	0.0307	CbGpPWpGaD
Metyrapone—Hypertension—Capecitabine—colon cancer	0.000221	0.0109	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000217	0.0107	CcSEcCtD
Metyrapone—ABCC3—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000216	0.0293	CbGpPWpGaD
Metyrapone—Dizziness—Vincristine—colon cancer	0.000212	0.0105	CcSEcCtD
Metyrapone—ABCC3—Fluoropyrimidine Activity—TYMS—colon cancer	0.000207	0.028	CbGpPWpGaD
Metyrapone—Dizziness—Irinotecan—colon cancer	0.000207	0.0102	CcSEcCtD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000206	0.0279	CbGpPWpGaD
Metyrapone—Nervous system disorder—Capecitabine—colon cancer	0.000205	0.0101	CcSEcCtD
Metyrapone—Vomiting—Vincristine—colon cancer	0.000204	0.0101	CcSEcCtD
Metyrapone—Skin disorder—Capecitabine—colon cancer	0.000203	0.01	CcSEcCtD
Metyrapone—Headache—Vincristine—colon cancer	0.000201	0.00994	CcSEcCtD
Metyrapone—Angiopathy—Methotrexate—colon cancer	0.000199	0.00984	CcSEcCtD
Metyrapone—Vomiting—Irinotecan—colon cancer	0.000199	0.00983	CcSEcCtD
Metyrapone—Dizziness—Fluorouracil—colon cancer	0.000198	0.00979	CcSEcCtD
Metyrapone—ABCC3—ABC-family proteins mediated transport—ABCB1—colon cancer	0.000196	0.0266	CbGpPWpGaD
Metyrapone—Headache—Irinotecan—colon cancer	0.000196	0.00968	CcSEcCtD
Metyrapone—Hypotension—Capecitabine—colon cancer	0.000195	0.00967	CcSEcCtD
Metyrapone—Alopecia—Methotrexate—colon cancer	0.000194	0.00958	CcSEcCtD
Metyrapone—Nausea—Vincristine—colon cancer	0.000191	0.00943	CcSEcCtD
Metyrapone—Vomiting—Fluorouracil—colon cancer	0.00019	0.00941	CcSEcCtD
Metyrapone—Headache—Fluorouracil—colon cancer	0.000187	0.00928	CcSEcCtD
Metyrapone—Nausea—Irinotecan—colon cancer	0.000186	0.00918	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Capecitabine—colon cancer	0.000181	0.00893	CcSEcCtD
Metyrapone—Pain—Capecitabine—colon cancer	0.000179	0.00885	CcSEcCtD
Metyrapone—Nausea—Fluorouracil—colon cancer	0.000178	0.00879	CcSEcCtD
Metyrapone—Gastrointestinal pain—Capecitabine—colon cancer	0.000171	0.00846	CcSEcCtD
Metyrapone—Abdominal pain—Capecitabine—colon cancer	0.000165	0.00818	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000161	0.00798	CcSEcCtD
Metyrapone—Nervous system disorder—Methotrexate—colon cancer	0.000153	0.00755	CcSEcCtD
Metyrapone—Skin disorder—Methotrexate—colon cancer	0.000151	0.00748	CcSEcCtD
Metyrapone—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00015	0.0204	CbGpPWpGaD
Metyrapone—Hypotension—Methotrexate—colon cancer	0.000145	0.0072	CcSEcCtD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000143	0.0194	CbGpPWpGaD
Metyrapone—Dizziness—Capecitabine—colon cancer	0.000138	0.00684	CcSEcCtD
Metyrapone—CYP2A6—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000135	0.0183	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Methotrexate—colon cancer	0.000134	0.00665	CcSEcCtD
Metyrapone—Pain—Methotrexate—colon cancer	0.000133	0.00659	CcSEcCtD
Metyrapone—Vomiting—Capecitabine—colon cancer	0.000133	0.00658	CcSEcCtD
Metyrapone—Headache—Capecitabine—colon cancer	0.000131	0.00648	CcSEcCtD
Metyrapone—CYP2A6—Fluoropyrimidine Activity—TYMS—colon cancer	0.000129	0.0176	CbGpPWpGaD
Metyrapone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—colon cancer	0.000129	0.0175	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Methotrexate—colon cancer	0.000127	0.0063	CcSEcCtD
Metyrapone—Nausea—Capecitabine—colon cancer	0.000124	0.00615	CcSEcCtD
Metyrapone—Abdominal pain—Methotrexate—colon cancer	0.000123	0.00609	CcSEcCtD
Metyrapone—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.000105	0.0142	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—CHST5—colon cancer	0.000104	0.0141	CbGpPWpGaD
Metyrapone—Dizziness—Methotrexate—colon cancer	0.000103	0.00509	CcSEcCtD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000102	0.0138	CbGpPWpGaD
Metyrapone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—colon cancer	0.000101	0.0138	CbGpPWpGaD
Metyrapone—Vomiting—Methotrexate—colon cancer	9.9e-05	0.0049	CcSEcCtD
Metyrapone—Headache—Methotrexate—colon cancer	9.75e-05	0.00482	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—CA7—colon cancer	9.67e-05	0.0131	CbGpPWpGaD
Metyrapone—Nausea—Methotrexate—colon cancer	9.25e-05	0.00457	CcSEcCtD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—BRAF—colon cancer	8.72e-05	0.0118	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CA7—colon cancer	8.33e-05	0.0113	CbGpPWpGaD
Metyrapone—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	8.22e-05	0.0111	CbGpPWpGaD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	7.08e-05	0.0096	CbGpPWpGaD
Metyrapone—CYP3A4—Irinotecan Pathway—APC—colon cancer	6.92e-05	0.00939	CbGpPWpGaD
Metyrapone—ABCC3—Fluoropyrimidine Activity—TP53—colon cancer	6.86e-05	0.0093	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—CASP3—colon cancer	6.54e-05	0.00887	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—CTNNB1—colon cancer	6.3e-05	0.00855	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CA7—colon cancer	6e-05	0.00814	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CHST5—colon cancer	5.86e-05	0.00795	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ODC1—colon cancer	5.86e-05	0.00795	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—TGFB1—colon cancer	5.09e-05	0.00691	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CHST5—colon cancer	5.05e-05	0.00685	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ODC1—colon cancer	5.05e-05	0.00685	CbGpPWpGaD
Metyrapone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	4.95e-05	0.00672	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	4.82e-05	0.00653	CbGpPWpGaD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	4.72e-05	0.0064	CbGpPWpGaD
Metyrapone—CYP2A6—Fluoropyrimidine Activity—TP53—colon cancer	4.3e-05	0.00583	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CA7—colon cancer	3.76e-05	0.0051	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ODC1—colon cancer	3.64e-05	0.00493	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CHST5—colon cancer	3.64e-05	0.00493	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—AKT1—colon cancer	3.54e-05	0.0048	CbGpPWpGaD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	3.28e-05	0.00446	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CA7—colon cancer	2.97e-05	0.00403	CbGpPWpGaD
Metyrapone—ABCC3—NRF2 pathway—TGFB1—colon cancer	2.53e-05	0.00344	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.42e-05	0.00328	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ODC1—colon cancer	2.28e-05	0.00309	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CHST5—colon cancer	2.28e-05	0.00309	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.08e-05	0.00283	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—ABCB1—colon cancer	2.05e-05	0.00278	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.9e-05	0.00258	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ODC1—colon cancer	1.8e-05	0.00244	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CHST5—colon cancer	1.8e-05	0.00244	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.64e-05	0.00222	CbGpPWpGaD
Metyrapone—CYP2A6—NRF2 pathway—TGFB1—colon cancer	1.59e-05	0.00215	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.58e-05	0.00215	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ABCB1—colon cancer	1.55e-05	0.0021	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—TYMS—colon cancer	1.52e-05	0.00206	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.5e-05	0.00204	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CA7—colon cancer	1.38e-05	0.00187	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.36e-05	0.00185	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ABCB1—colon cancer	1.33e-05	0.00181	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—TYMS—colon cancer	1.31e-05	0.00178	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.18e-05	0.0016	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.17e-05	0.00159	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PPARG—colon cancer	1.08e-05	0.00146	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.01e-05	0.00137	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.82e-06	0.00133	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ABCB1—colon cancer	9.61e-06	0.0013	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—TYMS—colon cancer	9.44e-06	0.00128	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PPARG—colon cancer	9.28e-06	0.00126	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTGS2—colon cancer	8.47e-06	0.00115	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ODC1—colon cancer	8.35e-06	0.00113	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CHST5—colon cancer	8.35e-06	0.00113	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTGS2—colon cancer	7.3e-06	0.000991	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.26e-06	0.000986	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—EP300—colon cancer	7.05e-06	0.000956	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PPARG—colon cancer	6.69e-06	0.000907	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—EP300—colon cancer	6.07e-06	0.000824	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ABCB1—colon cancer	6.02e-06	0.000817	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—TYMS—colon cancer	5.91e-06	0.000802	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTGS2—colon cancer	5.26e-06	0.000713	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CA—colon cancer	5.21e-06	0.000707	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ABCB1—colon cancer	4.76e-06	0.000645	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—TYMS—colon cancer	4.67e-06	0.000634	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CA—colon cancer	4.49e-06	0.00061	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—EP300—colon cancer	4.37e-06	0.000593	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—AKT1—colon cancer	4.26e-06	0.000578	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PPARG—colon cancer	4.19e-06	0.000568	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—AKT1—colon cancer	3.67e-06	0.000498	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PPARG—colon cancer	3.31e-06	0.000449	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTGS2—colon cancer	3.29e-06	0.000447	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CA—colon cancer	3.24e-06	0.000439	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—EP300—colon cancer	2.74e-06	0.000372	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—AKT1—colon cancer	2.64e-06	0.000359	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTGS2—colon cancer	2.6e-06	0.000353	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ABCB1—colon cancer	2.21e-06	0.000299	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TYMS—colon cancer	2.17e-06	0.000294	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—EP300—colon cancer	2.17e-06	0.000294	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CA—colon cancer	2.03e-06	0.000275	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—AKT1—colon cancer	1.66e-06	0.000225	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CA—colon cancer	1.6e-06	0.000217	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PPARG—colon cancer	1.54e-06	0.000208	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—AKT1—colon cancer	1.31e-06	0.000177	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTGS2—colon cancer	1.21e-06	0.000164	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—EP300—colon cancer	1e-06	0.000136	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CA—colon cancer	7.43e-07	0.000101	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—AKT1—colon cancer	6.07e-07	8.23e-05	CbGpPWpGaD
